Shorter drug treatment OK for many breast cancer patients

May 16, 2018 by Marilynn Marchione
This undated image made available by F. Hoffmann-La Roche shows a vial of the company's Herceptin medication. According to a study released on Wednesday, May 16, 2018, many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12, greatly reducing the risk of heart damage it can cause. (F. Hoffmann-La Roche via AP)

Many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12, greatly reducing the risk of heart damage it sometimes can cause, a study suggests.

It's good news, but it comes nearly two decades after the drug first went on the market and many patients have suffered that side effect.

The study was done in the United Kingdom and funded by UK government grants. Results were released Wednesday by the American Society of Clinical Oncology and will be presented at the group's meeting next month.

Herceptin transformed care of a dreaded disease when it was approved in 1998 for women with advanced breast cancers whose growth is aided by a faulty HER2 gene, as 15 percent to 20 percent of cases are. It was later approved for of those cancers in earlier stages, too, based on studies that had tested it in patients for 12 months. That guess, that the drug should be taken for a year, became the standard of care.

But the drug can hurt the heart's ability to pump. That often eases if treatment is stopped but the damage can be permanent and lead to heart failure.

Some studies tested shorter use, but results conflicted. The new study is the largest so far, and involved more than 4,000 women with early-stage cancers who were given usual chemotherapy plus Herceptin for either six or 12 months.

After four years, about 90 percent of both groups were alive without signs of the disease. Only 4 percent on the shorter treatment dropped out due to heart problems versus 8 percent of those treated for a year.

"It's great news" for patients, said the study leader, Dr. Helena Earl of the University of Cambridge in England. Earl has consulted for Herceptin's maker, Roche. The company had no role in the study.

"There's no reason to not immediately change practice. The findings are persuasive," said Dr. Richard Schilsky, chief medical officer for the oncology society. Most of Herceptin's -fighting benefit seems to come in the early months of use, he said.

Others said that because so few women have died or relapsed after being treated with the drug, longer followup may be needed to make sure the findings hold up before guidelines should be changed. Doctors also want to see results published, and to study them to see if certain groups of women need longer treatment.

Herceptin is given through an IV every three weeks; a year of it costs $34,000 to $40,000 in England and about $70,000 in the U.S. In December, a copycat competitor known as a biosimilar was approved in the U.S. and already is used in some other countries.

Dr. Harold Burstein, a breast cancer expert at Dana-Farber Cancer Institute in Boston, said shorter treatment may increase access to the drug in countries where many women can't afford it now, but that in the U.S., "my guess is that people will continue to aim for a year of treatment" because of lingering concerns that longer use is better, as a smaller, previous study suggested.

Dr. Jennifer Litton, a breast specialist at MD Anderson Cancer Center in Houston, said Herceptin was a true breakthrough, but scaling back treatment whenever possible is just as important to patients. She said the results show how important it can be to study drugs already on the market, and that companies alone should not be relied on to do studies like this.

"It's really important that we continue to have public funding for trials so we can continue to ask all of these questions for our patients," she said.

Earlier this year, the American Heart Association issued its first statement on the heart effects of cancer drugs, saying should consider carefully the risks and benefits of any therapies that may hurt hearts.

Explore further: Study: Two drugs prevent heart problems in breast cancer patients

Related Stories

Study: Two drugs prevent heart problems in breast cancer patients

March 11, 2018
Data released today from a large multi-center study provides a view into the effectiveness of two drugs used to prevent heart problems resulting from breast cancer treatment.

Doctors warn of heart risk from some breast cancer therapies

February 1, 2018
Save your life but harm your heart? Health experts are sounding a warning as potential side effects of a growing number of breast cancer treatments come to light.

Cheaper breast cancer drug does well in clinical trial

June 3, 2016
(HealthDay)—For women with advanced HER2-positive breast cancer, a similar but less expensive experimental drug works just as well as the standard drug Herceptin (trastuzumab), a new study finds.

Breast cancer treatment and heart disease—what you need to know

February 14, 2018
Recently, the American Heart Association published a striking statement for women who have undergone chemotherapy and/or radiation treatment for breast cancer: namely, that these therapies can contribute to heart failure ...

Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm

June 11, 2014
In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug Trastuzumab (Herceptin) is associated with prolonged survival but also increases the risk of developing heart problems, a new systematic ...

Drugs score big wins against lung, prostate, breast cancers

June 5, 2017
Drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There's even a "uni-drug" that may fight many forms of the disease.

Recommended for you

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Method identified to reduce risk of brain damage in leukemia survivors

September 25, 2018
Children with acute lymphoblastic leukemia (ALL) are at an extremely high risk of sepsis compared to the general population. In the first-published study of its kind, St. Jude Children's Research Hospital scientists have ...

Unhealthy lifestyle responsible for 45,000 predicted cases of bowel cancer in next decade

September 25, 2018
A UNSW study shows that a large proportion of bowel cancers in Australia are preventable by adopting a healthy lifestyle – particularly for men.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.